Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 19Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × cabozantinib × Clear all
NCT03634540 2024-12-20

MK-6482-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
118 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡